Novo Nordisk AS together with its subsidiaries engages in the research and development manufacture and distribution of pharmaceutical products in Europe the Middle East Africa Mainland China Hong Kong Taiwan North America and internationally It operates in two segments Diabetes and Obesity Care and Rare Disease The Diabetes and Obesity care segment provides products for diabetes obesity cardiovascular and other emerging therapy areas The Rare Disease segment offers products in the areas of rare blood disorders rare endocrine disorders and hormone replacement therapy The company also provides insulin pens growth hormone pens and injection needles In addition it offers smart solutions for diabetes treatment such as smart insulin pens and Dose Check an insulin dose guidance application The company has a collaboration agreement with UNICEF to tackle childhood obesity and with Valo Health Inc to discover and develop novel drug programmes for cardiometabolic space Novo Nordisk AS was founded in 1923 and is headquartered in Bagsvaerd Denmark
0.00%
Last week
1 Week Post-Dividend Price Movement
Price Movement Trend 43.5% upward movements, 4.3% stable prices after dividend payments
Warning: include(/home/individends/public_html/dividend-content.php?ajax=true&ticker=NVO): Failed to open stream: No such file or directory in /home/individends/public_html/stock.php on line 708
Warning: include(): Failed opening '/home/individends/public_html/dividend-content.php?ajax=true&ticker=NVO' for inclusion (include_path='.:/opt/cpanel/ea-php83/root/usr/share/pear') in /home/individends/public_html/stock.php on line 708
Novo Nordisk AS (NVO) Profile
Novo Nordisk AS together with its subsidiaries engages in the research and development manufacture and distribution of pharmaceutical products in Europe the Middle East Africa Mainland China Hong Kong Taiwan North America and internationally It operates in two segments Diabetes and Obesity Care and Rare Disease The Diabetes and Obesity care segment provides products for diabetes obesity cardiovascular and other emerging therapy areas The Rare Disease segment offers products in the areas of rare blood disorders rare endocrine disorders and hormone replacement therapy The company also provides insulin pens growth hormone pens and injection needles In addition it offers smart solutions for diabetes treatment such as smart insulin pens and Dose Check an insulin dose guidance application The company has a collaboration agreement with UNICEF to tackle childhood obesity and with Valo Health Inc to discover and develop novel drug programmes for cardiometabolic space Novo Nordisk AS was founded in 1923 and is headquartered in Bagsvaerd Denmark